XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.20.2

Inventory | 6 Months Ended
--- | ---
Jun. 30, 2020
Inventory Disclosure [Abstract] |
Inventory | Inventory As of June 30, 2020 and December 31, 2019, the Company's inventory balance consists of the following (in thousands):
| June 30, 2020 |  | December 31, 2019
Raw materials | $ | 17,270 |  |  | $ | 16,048 |
Work-in-process | 9,089 |  |  | 6,420 |
Finished goods | 9,114 |  |  | 5,845 |
| $ | 35,473 |  |  | $ | 28,313 |
Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration